KENNETH MCCLAIN to Risk Factors
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Risk Factors.
Connection Strength
0.111
-
A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
Score: 0.023
-
Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005 Nov; 6(14):2435-41.
Score: 0.022
-
Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol. 2002 Jul; 39(1):35-9.
Score: 0.017
-
Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018 10; 19(10):e522-e530.
Score: 0.013
-
Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.012
-
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
Score: 0.010
-
Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010 Jun; 156(6):873-881.e1.
Score: 0.007
-
Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003 May 14; 289(18):2393-9.
Score: 0.005
-
Incidence of childhood and adolescent cancer in Texas. Tex Med. 1996 Jul; 92(7):54-60.
Score: 0.003